Tuesday 31 October, 12-1pm, Seminar Room 1, TRF
Chronic liver diseases are characterised by progressive hepatocyte
injury, which results in wound healing responses, inflammation and the
accumulation of extracellular matrix (ECM).
The size of the population affected with chronic liver disease has been
disproportionally increased, and the costs of this increase are enormous. There
are many causes of chronic liver disease including viral hepatitis, alcoholic
liver disease and non-alcoholic fatty liver disease. Currently, the only effective treatment for end-stage
liver disease is orthotopic liver transplantation (OLT). Human Amniotic
Epithelial Cells (hAECs) are isolated from the amnion of the placenta in
sufficient numbers for clinical use, and bear many characteristics of
traditional stem cells including pluripotent ability, low immunogenicity,
anti-inflammatory and anti-fibrotic effects. Extracellular vesicles (EVs)
are complex membrane enclosed nanoparticles that carry a cargo of select
proteins, RNAs, and lipids. I will explore the therapeutic efficacy of hAECs
and hAEC-EV in reducing hepatic fibrosis. Mr Majid Alhomrani is a scientist at
Monash University where he is currently in his third year of PhD.
No comments:
Post a Comment